Firstly, sotagliflozin significantly reduces the overall incidence of CV death, heart failure hospitalizations, and urgent heart failure visits; (Bhatt et al., 2021b);Secondly, as an oral double-acting inhibitor of SGLT-1/SGLT-2, sotagliflozin markedly lowers glycated hemoglobin (HbA1c) levels in patients with alleviate to moderately severe chronic kidney disease (CKD), demonstrating significant efficacy individual with CKD. The gene discussed is SLC5A2; the disease is heart failure.